JTCS Medtronic Endurant
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Francesco Patanè
Edoardo Zingarelli
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Patanè, F.
Right arrow Articles by La Torre, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Patanè, F.
Right arrow Articles by La Torre, M.
Related Collections
Right arrow Extracorporeal circulation
Right arrow Mechanical Circulatory Assistance
Right arrow Transplantation - heart

J Thorac Cardiovasc Surg 2009;137:1288-1289
© 2009 The American Association for Thoracic Surgery

Brief Communication

Potential role of the Impella Recover left ventricular assist device in the management of postinfarct ventricular septal defect

Francesco Patanè, MDa,*, Paolo Centofanti, MDa, Edoardo Zingarelli, MDb, Fabrizio Sansone, MDa, Michele La Torre, MDa

a Cardiac Surgery Department, San Giovanni Battista Hospital, Turin, Italy
b Cardiac Surgery Department, Mauriziano Hospital, Turin, Italy

Received for publication January 18, 2008; accepted for publication February 23, 2008.

* Address for reprints: Francesco Patanè, MD, Divisione di Cardiochirurgia, Ospedale San Giovanni Battista, C.so Bramante 88, Torino, Italia. (Email: f_patane@hotmail.com).

The first 20% of the full text of this article appears below.

Postinfarction ventricular septal defect (VSD) remains a dangerous complication after acute myocardial infarction with regard to both natural history and surgical treatment. VSD appears in 1% to 2% of patients after a myocardial infarction. Prognosis is poor, with only 75% of untreated patients surviving after 24 hours, 50% after 1 week, 30% after 2 weeks, and only 15% after 30 days.1Go The literature describes different outcomes depending on whether the corrective operation is performed promptly or deferred; mortality is 67% if surgery is performed in the first week after postinfarction VSD develops, 75% if in the second week, and 17% after that.2Go

Clinical Summary

The Impella Recover (ABIOMED, Inc, Danvers, Mass) is a small intracardiac axial-flow left ventricular assist device (LVAD) that provides 4 to 5 L/min continuous blood flow. The device can be set at 10 different speeds, from 10,000 to 33,000 rpm. The Impella is advanced into the left ventricular cavity in a retrograde fashion through a prosthetic graft sutured to . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2009 by The American Association for Thoracic Surgery.